SI1883698T1 - Monoklonska protitelesa in enoverižni protitelesni fragmenti proti celičnemu površinskemu membranskemu antigenu, specifičnemu za prostato - Google Patents

Monoklonska protitelesa in enoverižni protitelesni fragmenti proti celičnemu površinskemu membranskemu antigenu, specifičnemu za prostato

Info

Publication number
SI1883698T1
SI1883698T1 SI200630996T SI200630996T SI1883698T1 SI 1883698 T1 SI1883698 T1 SI 1883698T1 SI 200630996 T SI200630996 T SI 200630996T SI 200630996 T SI200630996 T SI 200630996T SI 1883698 T1 SI1883698 T1 SI 1883698T1
Authority
SI
Slovenia
Prior art keywords
monoclonal antibodies
prostate specific
specific membrane
membrane antigen
antibody fragments
Prior art date
Application number
SI200630996T
Other languages
English (en)
Other versions
SI1883698T2 (sl
Inventor
Ursula Elsasser-Beile
Philipp Wolf
Dorothee Gierschner
Patrick Buhler
Ulrich Wetterauer
Original Assignee
Universitaetsklinikum Freiburg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34937022&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI1883698(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Universitaetsklinikum Freiburg filed Critical Universitaetsklinikum Freiburg
Publication of SI1883698T1 publication Critical patent/SI1883698T1/sl
Publication of SI1883698T2 publication Critical patent/SI1883698T2/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6869—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from a cell of the reproductive system: ovaria, uterus, testes, prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A61K51/1072—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from the reproductive system, e.g. ovaria, uterus, testes or prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/626—Diabody or triabody
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/80—Immunoglobulins specific features remaining in the (producing) cell, i.e. intracellular antibodies or intrabodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Reproductive Health (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gynecology & Obstetrics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SI200630996T 2005-05-27 2006-03-02 Monoklonska protitelesa in enoverižni protitelesni fragmenti proti celičnemu površinskemu membranskemu antigenu, specifičnemu za prostato SI1883698T2 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP05011536A EP1726650A1 (en) 2005-05-27 2005-05-27 Monoclonal antibodies and single chain antibody fragments against cell-surface prostate specific membrane antigen
PCT/EP2006/001917 WO2006125481A1 (en) 2005-05-27 2006-03-02 Monoclonal antibodies and single chain antibody fragments against cell-surface prostate specific membrane antigen
EP06707388.2A EP1883698B2 (en) 2005-05-27 2006-03-02 Monoclonal antibodies and single chain antibody fragments against cell-surface prostate specific membrane antigen

Publications (2)

Publication Number Publication Date
SI1883698T1 true SI1883698T1 (sl) 2011-06-30
SI1883698T2 SI1883698T2 (sl) 2015-11-30

Family

ID=34937022

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200630996T SI1883698T2 (sl) 2005-05-27 2006-03-02 Monoklonska protitelesa in enoverižni protitelesni fragmenti proti celičnemu površinskemu membranskemu antigenu, specifičnemu za prostato

Country Status (16)

Country Link
US (3) US8198416B2 (sl)
EP (3) EP1726650A1 (sl)
JP (4) JP5038297B2 (sl)
CN (1) CN101233236B (sl)
AT (1) ATE505544T1 (sl)
AU (1) AU2006251445B2 (sl)
CA (1) CA2609682C (sl)
CY (1) CY1111409T1 (sl)
DE (1) DE602006021296D1 (sl)
DK (1) DK1883698T4 (sl)
ES (1) ES2362795T5 (sl)
PL (1) PL1883698T5 (sl)
PT (1) PT1883698E (sl)
RU (1) RU2458073C2 (sl)
SI (1) SI1883698T2 (sl)
WO (1) WO2006125481A1 (sl)

Families Citing this family (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7105159B1 (en) 1992-11-05 2006-09-12 Sloan-Kettering Institute For Cancer Research Antibodies to prostate-specific membrane antigen
US20050215472A1 (en) 2001-10-23 2005-09-29 Psma Development Company, Llc PSMA formulations and uses thereof
EP3184539A3 (en) 2001-10-23 2017-09-13 PSMA Development Company L.L.C. Psma antibodies
EP1726650A1 (en) * 2005-05-27 2006-11-29 Universitätsklinikum Freiburg Monoclonal antibodies and single chain antibody fragments against cell-surface prostate specific membrane antigen
GB0715542D0 (en) * 2007-08-09 2007-09-19 Imp Innovations Ltd Methods
CN101910197B (zh) 2007-11-30 2014-09-24 卡罗拜奥斯制药公司 针对铜绿假单胞菌pcrv抗原的抗体
CA2721169A1 (en) * 2008-04-14 2009-10-22 Proscan Rx Pharma Inc. Prostate specific membrane antigen antibodies and antigen binding fragments
ITTO20080313A1 (it) 2008-04-22 2009-10-23 Marco Colombatti Anticorpo monoclonale isolato o suo frammento legante l'antigene specifico di membrana della prostata, suoi coniugati e suoi usi
PT2356153T (pt) * 2008-10-01 2016-07-15 Amgen Res (Munich) Gmbh Anticorpo biespecífico, de cadeia única, amepxcd3, específico interespécies
DK2352763T4 (da) * 2008-10-01 2022-10-17 Amgen Res Munich Gmbh Bispecifikke enkeltkædede antistoffer med specificitet for højmolekylære målantigener
EP2398504B1 (en) * 2009-02-17 2018-11-28 Cornell Research Foundation, Inc. Methods and kits for diagnosis of cancer and prediction of therapeutic value
TWI629357B (zh) * 2009-10-02 2018-07-11 安進研究（慕尼黑）有限責任公司 跨物種特異性的ＰＳＭＡｘＣＤ３雙特異性單鏈抗體
MX354143B (es) * 2009-12-02 2018-02-14 Imaginab Inc Minicuerpos j591 y diacuerpos-cys para apuntar con especificidad de objetivo a un antígeno de membrana específico para próstata de humano (psma) y métodos para su uso.
TWI653333B (zh) * 2010-04-01 2019-03-11 安進研究（慕尼黑）有限責任公司 跨物種專一性之ＰＳＭＡｘＣＤ３雙專一性單鏈抗體
MY171343A (en) 2011-04-22 2019-10-09 Aptevo Res & Development Llc Prostate-specific membrane antigen binding proteins and related composition and methods
WO2013155605A1 (en) * 2012-04-19 2013-10-24 Innovascreen Inc. Method for predicting a pathophysiological condition in an animal
ES2939760T3 (es) 2014-03-15 2023-04-26 Novartis Ag Tratamiento de cáncer utilizando un receptor quimérico para antígenos
JP2017528433A (ja) 2014-07-21 2017-09-28 ノバルティス アーゲー 低い免疫増強用量のｍＴＯＲ阻害剤とＣＡＲの組み合わせ
US20180334490A1 (en) 2014-12-03 2018-11-22 Qilong H. Wu Methods for b cell preconditioning in car therapy
US11161907B2 (en) 2015-02-02 2021-11-02 Novartis Ag Car-expressing cells against multiple tumor antigens and uses thereof
WO2016172583A1 (en) 2015-04-23 2016-10-27 Novartis Ag Treatment of cancer using chimeric antigen receptor and protein kinase a blocker
EP3297672B1 (en) 2015-05-21 2021-09-01 Harpoon Therapeutics, Inc. Trispecific binding proteins and methods of use
WO2017027392A1 (en) 2015-08-07 2017-02-16 Novartis Ag Treatment of cancer using chimeric cd3 receptor proteins
UA126278C2 (uk) 2015-09-21 2022-09-14 Аптево Рісьорч Енд Девелопмент Ллс Поліпептиди, які зв'язують cd3
WO2017091786A1 (en) 2015-11-23 2017-06-01 Novartis Ag Optimized lentiviral transfer vectors and uses thereof
SG11201805451TA (en) 2015-12-30 2018-07-30 Novartis Ag Immune effector cell therapies with enhanced efficacy
CN105524171A (zh) * 2016-02-03 2016-04-27 中国人民解放军第三军医大学第三附属医院 一种针对前列腺特异性膜抗原的纳米抗体
CN105968203A (zh) * 2016-02-03 2016-09-28 南昌大学 一种抗前列腺特异性膜抗原胞外区的单域重链抗体
CN105542009A (zh) * 2016-02-03 2016-05-04 南昌大学 一种针对前列腺特异性膜抗原的单域重链抗体
CN105968201A (zh) * 2016-02-03 2016-09-28 南昌大学 针对前列腺特异性膜抗原的单域重链抗体
CN105504061A (zh) * 2016-02-03 2016-04-20 南昌大学 针对前列腺特异性膜抗原的纳米抗体
CN105968202A (zh) * 2016-02-03 2016-09-28 南昌大学 针对前列腺特异性膜抗原胞外区的单域重链抗体
SG11201807489PA (en) 2016-03-04 2018-09-27 Novartis Ag Cells expressing multiple chimeric antigen receptor (car) molecules and uses therefore
EP3432924A1 (en) 2016-03-23 2019-01-30 Novartis AG Cell secreted minibodies and uses thereof
KR20180134385A (ko) 2016-04-15 2018-12-18 노파르티스 아게 선택적 단백질 발현을 위한 조성물 및 방법
JP7101621B2 (ja) 2016-05-20 2022-07-15 ハープーン セラピューティクス，インク． 単一ドメイン血清アルブミン結合タンパク質
AU2017267793B2 (en) 2016-05-20 2024-01-25 Harpoon Therapeutics, Inc. Single chain variable fragment CD3 binding proteins
US11623958B2 (en) 2016-05-20 2023-04-11 Harpoon Therapeutics, Inc. Single chain variable fragment CD3 binding proteins
JP2019527696A (ja) 2016-08-01 2019-10-03 ノバルティス アーゲー プロｍ２マクロファージ分子の阻害剤と組み合わせてキメラ抗原受容体を用いる癌の処置
CN110198955A (zh) * 2016-11-23 2019-09-03 哈普恩治疗公司 前列腺特异性膜抗原结合蛋白质
US10844134B2 (en) 2016-11-23 2020-11-24 Harpoon Therapeutics, Inc. PSMA targeting trispecific proteins and methods of use
WO2018111340A1 (en) 2016-12-16 2018-06-21 Novartis Ag Methods for determining potency and proliferative function of chimeric antigen receptor (car)-t cells
WO2018140725A1 (en) 2017-01-26 2018-08-02 Novartis Ag Cd28 compositions and methods for chimeric antigen receptor therapy
WO2018144535A1 (en) 2017-01-31 2018-08-09 Novartis Ag Treatment of cancer using chimeric t cell receptor proteins having multiple specificities
EP3589647A1 (en) 2017-02-28 2020-01-08 Novartis AG Shp inhibitor compositions and uses for chimeric antigen receptor therapy
EP3589662A4 (en) 2017-02-28 2020-12-30 Harpoon Therapeutics, Inc. INDUCTIBLE MONOVALENT ANTIGBINDING PROTEIN
CA3063362A1 (en) 2017-05-12 2018-11-15 Harpoon Therapeutics, Inc. Msln targeting trispecific proteins and methods of use
AU2018265856B2 (en) 2017-05-12 2023-04-27 Harpoon Therapeutics, Inc. Mesothelin binding proteins
WO2018229715A1 (en) 2017-06-16 2018-12-20 Novartis Ag Compositions comprising anti-cd32b antibodies and methods of use thereof
CR20200196A (es) 2017-10-13 2020-06-05 Harpoon Therapeutics Inc Proteínas trispecìficas y mètodos de uso
SG11202003341UA (en) 2017-10-13 2020-05-28 Harpoon Therapeutics Inc B cell maturation antigen binding proteins
US11999802B2 (en) 2017-10-18 2024-06-04 Novartis Ag Compositions and methods for selective protein degradation
BR112020007710A2 (pt) 2017-10-25 2020-10-20 Novartis Ag métodos para produzir células que expressam receptor de antígeno quimérico
US20210040205A1 (en) 2017-10-25 2021-02-11 Novartis Ag Antibodies targeting cd32b and methods of use thereof
WO2019089798A1 (en) 2017-10-31 2019-05-09 Novartis Ag Anti-car compositions and methods
EP3724231A4 (en) * 2017-12-12 2021-08-11 MacroGenics, Inc. BISPECIFIC CD16 BINDING MOLECULES AND THEIR USES IN THE TREATMENT OF DISEASES
EP3773740A1 (en) 2018-04-13 2021-02-17 Heidelberg Pharma Research GmbH Targeted amatoxin conjugate for the treatment of solid tumors
EP3784351A1 (en) 2018-04-27 2021-03-03 Novartis AG Car t cell therapies with enhanced efficacy
EP3788369A1 (en) 2018-05-01 2021-03-10 Novartis Ag Biomarkers for evaluating car-t cells to predict clinical outcome
EP3801769A1 (en) 2018-05-25 2021-04-14 Novartis AG Combination therapy with chimeric antigen receptor (car) therapies
WO2019237035A1 (en) 2018-06-08 2019-12-12 Intellia Therapeutics, Inc. Compositions and methods for immunooncology
EP3587454A1 (en) * 2018-06-27 2020-01-01 Albert-Ludwigs-Universität Freiburg Chimeric antigen receptors that bind to prostate specific membrane antigen
AR116109A1 (es) 2018-07-10 2021-03-31 Novartis Ag Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
JP2021532778A (ja) * 2018-07-31 2021-12-02 ハイデルベルク ファルマ リサーチ ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｐｓｍａに対するヒト化抗体
US10815311B2 (en) 2018-09-25 2020-10-27 Harpoon Therapeutics, Inc. DLL3 binding proteins and methods of use
CA3123511A1 (en) 2018-12-20 2020-06-25 Novartis Ag Dosing regimen and pharmaceutical combination comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
KR20210129672A (ko) 2019-02-15 2021-10-28 노파르티스 아게 치환된 3-(1-옥소이소인돌린-2-일)피페리딘-2,6-디온 유도체 및 이의 용도
US20220144807A1 (en) 2019-02-15 2022-05-12 Novartis Ag 3-(1-oxo-5-(piperidin-4-yl)isoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
CN110407939B (zh) * 2019-03-12 2023-09-29 广东医科大学附属第二医院 一种人源化抗psma单链抗体及其应用
WO2020219742A1 (en) 2019-04-24 2020-10-29 Novartis Ag Compositions and methods for selective protein degradation
CN115175937A (zh) 2019-12-20 2022-10-11 诺华股份有限公司 用于治疗骨髓纤维化和骨髓增生异常综合征的抗TIM-3抗体MBG453和抗TGF-β抗体NIS793与或不与地西他滨或抗PD-1抗体斯巴达珠单抗的组合
EP3842461A1 (en) 2019-12-23 2021-06-30 Albert-Ludwigs-Universität Freiburg Chimeric antigen receptors that bind to prostate specific membrane antigen
WO2021164692A1 (zh) * 2020-02-18 2021-08-26 和铂医药(上海)有限责任公司 一种分离的结合抗原psma的蛋白及其用途
CN111303288B (zh) * 2020-03-04 2020-12-25 和铂医药(苏州)有限公司 一种分离的结合抗原psma的蛋白及其用途
JP2023527609A (ja) 2020-02-21 2023-06-30 ハープーン セラピューティクス，インク． Ｆｌｔ３結合タンパク質および使用方法
JP7390214B2 (ja) 2020-02-28 2023-12-01 株式会社東京精密 シリコンウエハ表面状態診断方法及び表面改質方法
IL298473A (en) 2020-06-11 2023-01-01 Novartis Ag zbtb32 inhibitors and uses thereof
WO2021260528A1 (en) 2020-06-23 2021-12-30 Novartis Ag Dosing regimen comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
JP2023536164A (ja) 2020-08-03 2023-08-23 ノバルティス アーゲー ヘテロアリール置換３－（１－オキソイソインドリン－２－イル）ピペリジン－２，６－ジオン誘導体及びその使用
TW202304979A (zh) 2021-04-07 2023-02-01 瑞士商諾華公司 抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途
AR125468A1 (es) 2021-04-27 2023-07-19 Novartis Ag Sistema de producción de vectores virales
WO2023214325A1 (en) 2022-05-05 2023-11-09 Novartis Ag Pyrazolopyrimidine derivatives and uses thereof as tet2 inhibitors
WO2024089639A1 (en) 2022-10-26 2024-05-02 Novartis Ag Lentiviral formulations

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5162504A (en) * 1988-06-03 1992-11-10 Cytogen Corporation Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients
US6255458B1 (en) * 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
ZA94916B (en) * 1993-02-10 1995-08-10 Unilever Plc Immobilized proteins with specific binding capacities and their use in processes and products
ATE318147T1 (de) * 1996-03-25 2006-03-15 Medarex Inc Spezifische monoklonale antikörperfür die extrazelluläre domäne von protasta-spezifischem membranantigen
US6150508A (en) * 1996-03-25 2000-11-21 Northwest Biotherapeutics, Inc. Monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen
US6107090A (en) * 1996-05-06 2000-08-22 Cornell Research Foundation, Inc. Treatment and diagnosis of prostate cancer with antibodies to extracellur PSMA domains
HUP0001441A3 (en) * 1997-02-26 2001-03-28 Sankyo Company Ltd Chuo Ku Process for the preparation of pharmaceutical compositions containing 4-aza-androst-1-ene derivatives
US6258939B1 (en) * 1997-03-10 2001-07-10 The Regents Of The University Of California PSCA antibodies and hybridomas producing them
ATE342282T1 (de) * 1999-07-29 2006-11-15 Medarex Inc Humane monoklonale antikörper gegen prostata spezifisches membranantigen
FR2797743B1 (fr) * 1999-08-23 2003-08-08 Urogene Lignee cellulaire prostatique et son utilisation pour l'obtention d'une tumeur prostatique etablie chez l'animal
WO2002098897A2 (en) * 2001-06-01 2002-12-12 Cornell Research Foundation, Inc. Modified antibodies to prostate-specific membrane antigen and uses thereof
JP2005518336A (ja) * 2001-06-26 2005-06-23 イムクローン システムズ インコーポレイティド Ｖｅｇｆ受容体に結合する二重特異性抗体
WO2003024388A2 (en) * 2001-09-20 2003-03-27 Cornell Research Foundation, Inc. Methods and compositions for treating and preventing skin disorders using binding agents specific for psma
EP3184539A3 (en) * 2001-10-23 2017-09-13 PSMA Development Company L.L.C. Psma antibodies
CA2474616A1 (en) * 2002-01-28 2003-08-07 Medarex, Inc. Human monoclonal antibodies to prostate specific membrane antigen (psma)
JP2004000045A (ja) * 2002-05-31 2004-01-08 Kyowa Hakko Kogyo Co Ltd 前立腺特異的膜抗原に対する抗体
US6641899B1 (en) * 2002-11-05 2003-11-04 International Business Machines Corporation Nonlithographic method to produce masks by selective reaction, articles produced, and composition for same
US7811564B2 (en) * 2003-01-28 2010-10-12 Proscan Rx Pharma Prostate cancer diagnosis and treatment
EP1841467A4 (en) * 2005-01-14 2009-01-28 Cytogen Corp COMBINATION CANCER THERAPY WITH ANTI-PSMA ANTIBODIES
WO2006089230A2 (en) * 2005-02-18 2006-08-24 Medarex, Inc. Human monoclonal antibodies to prostate specific membrane antigen (psma)
JP5249587B2 (ja) * 2005-02-18 2013-07-31 メダレックス， インク． フコシル残基を欠く前立腺特異的膜抗原（ｐｓｍａ）に対するモノクローナル抗体
CA2603847A1 (en) * 2005-04-08 2006-10-19 Cytogen Corporation Conjugated anti-psma antibodies
EP1726650A1 (en) * 2005-05-27 2006-11-29 Universitätsklinikum Freiburg Monoclonal antibodies and single chain antibody fragments against cell-surface prostate specific membrane antigen
CA2612762C (en) * 2005-06-20 2013-12-10 Psma Development Company, Llc Psma antibody-drug conjugates

Also Published As

Publication number Publication date
ES2362795T3 (es) 2011-07-13
JP5524270B2 (ja) 2014-06-18
EP1883698A1 (en) 2008-02-06
AU2006251445A2 (en) 2006-11-30
ATE505544T1 (de) 2011-04-15
US8198416B2 (en) 2012-06-12
CA2609682A1 (en) 2006-11-30
US8632777B2 (en) 2014-01-21
DK1883698T4 (en) 2015-10-12
RU2007147596A (ru) 2009-07-10
DE602006021296D1 (de) 2011-05-26
JP6110321B2 (ja) 2017-04-05
EP1883698B2 (en) 2015-09-09
US20120231024A1 (en) 2012-09-13
US20140155583A1 (en) 2014-06-05
JP2012197278A (ja) 2012-10-18
PL1883698T5 (pl) 2016-02-29
CN101233236A (zh) 2008-07-30
JP2008541711A (ja) 2008-11-27
WO2006125481A1 (en) 2006-11-30
EP1883698B1 (en) 2011-04-13
DK1883698T3 (da) 2011-06-06
US20090041789A1 (en) 2009-02-12
JP5038297B2 (ja) 2012-10-03
CN101233236B (zh) 2012-11-28
AU2006251445B2 (en) 2010-11-18
JP2014141491A (ja) 2014-08-07
JP2016190839A (ja) 2016-11-10
CY1111409T1 (el) 2015-08-05
US9238694B2 (en) 2016-01-19
AU2006251445A9 (en) 2006-11-30
AU2006251445A1 (en) 2006-11-30
RU2458073C2 (ru) 2012-08-10
EP2363486A1 (en) 2011-09-07
CA2609682C (en) 2019-06-04
PL1883698T3 (pl) 2011-08-31
ES2362795T5 (es) 2015-11-06
EP1726650A1 (en) 2006-11-29
SI1883698T2 (sl) 2015-11-30
PT1883698E (pt) 2011-06-28

Similar Documents

Publication Publication Date Title
PT1883698E (pt) Anticorpos monoclonais e fragmentos de anticorpo de cadeia única contra antigénio de membrana específico da próstata de superfície celular
HUS1700028I1 (hu) Antitestek a Clostridium difficile toxinok ellen és azok felhasználásai
WO2006099141A3 (en) Anti-mesothelin antibodies
PH12016501691A1 (en) Antibodies to matrix metalloproteinase 9
TW200616662A (en) Humanized anti-5t4 antibodies and anti-5t4 antibody/calicheamicin conjugates
TW200639182A (en) Antibody variants and uses thereof
HK1074634A1 (en) Internalizing antibodies specific for the raag10 cell surface target
RS54424B1 (en) HUMAN ANTIBODIES CONCERNING CXCR4 AND THEIR USES
NZ597563A (en) Muc1 antibodies
WO2007109321A3 (en) Engineered anti-prostate stem cell antigen (psca) antibodies for cancer targeting
ES2639026T3 (es) Anticuerpos totalmente humanos específicos para CADM1
NZ597447A (en) Humanised antibodies to toll-like receptor 2 and uses thereof
WO2005090406A3 (en) Antibodies binding to ephb4 for inhibiting angiogenesis and tumor growth
MX2010001237A (es) Nuevos anticuerpos.
WO2007144619A3 (en) Antibodies selectively binding aggregated prion protein 106-126 and uses thereof
MX2009008754A (es) Anticuerpos novedosos contra igf-1r.
WO2007076465A3 (en) Cln248 antibody compositions and methods of use
HK1116198A1 (en) Antibodies binding to ephb4 for inhibiting angiogenesis and tumor growth